PLUS1
2.06
-0.12 (-5.5%)
-0.12 (-5.5%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Ocugen Inc | OCGN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.12 | -5.5% | 2.06 | 17:38:34 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.0732 | 2.00 | 2.15 | 2.08 | 2.18 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 2.06 | 2.07 | 0.01 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 43,743 | 23,394,275 | $ 2.06 | $ 48,210,407 | 86,255,326 | 0.17 - 3.495 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:38:28 | 3 | $ 2.06 | USD |
Ocugen Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 333.77M | 162.03M | 156.81M | $ - | $ - | -8.42 | 0.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Ocugen News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/12/2021 | 12:06 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/12/2021 | 12:03 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) |
| 1/12/2021 | 07:52 | GlobeNewswire Inc. | Ocugen Inc. Announces the Cancellation of Stockholder.. |
| 1/08/2021 | 16:02 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/08/2021 | 15:17 | GlobeNewswire Inc. | Ocugen Inc. Regains Compliance with Nasdaq Bid Price Rule |
| 1/08/2021 | 08:00 | GlobeNewswire Inc. | Ocugen Inc. to Present at CTIC, HC Wainwright and Noble.. |
| 1/05/2021 | 17:24 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OCGN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.4432 | 2.45 | 2.00 | 2.26 | 18,226,797 | -0.3832 | -15.68% |
| 1 Month | 2.39 | 3.495 | 1.72 | 2.50 | 42,805,539 | -0.33 | -13.81% |
| 3 Months | 0.2899 | 3.495 | 0.2501 | 1.83 | 51,399,056 | 1.77 | 610.59% |
| 6 Months | 0.4498 | 3.495 | 0.2501 | 1.39 | 35,564,810 | 1.61 | 357.98% |
| 1 Year | 0.66 | 3.495 | 0.17 | 1.16 | 22,642,573 | 1.40 | 212.12% |
| 3 Years | 3.24 | 3.495 | 0.17 | 1.12 | 18,642,382 | -1.18 | -36.42% |
| 5 Years | 3.24 | 3.495 | 0.17 | 1.12 | 18,642,382 | -1.18 | -36.42% |
Ocugen Description
| Ocugen Inc is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases. Its product candidate includes OCU200 and OCU300 to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet age-related macular degeneration (AMD). |
